Maternal concentrations of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 1 (IGFBP-1) may influence fetal growth. Offspring birth weight related to maternal IGF-I and IGFBP-1 measured in pregnancy was studied in 368 randomly selected women without preeclampsia who delivered a singleton liveborn child in Norway between 1992 and 1994. Maternal IGF-I concentrations were not consistently associated with birth weight, but a 1-standard deviation stronger increase in IGF-I from the first to second trimester was associated with an 82-g (95% confidence interval (CI): 11, 153) higher birth weight. IGFBP-1 concentrations were inversely associated with birth weight: Birth weight was 71 g (95% CI: 14, 128) lower per 1-standard deviation higher IGFBP-1 in the second trimester, and an increase in IGFBP-1 from the first (below median) to second (above median) trimester was associated with a 342-g (95% CI: 124, 560) lower birth weight, compared with having low
Insulin-like growth factors (IGFs) in the fetal circulation are necessary for normal growth and development (1) , but it is not resolved whether IGFs in the maternal circulation are important for fetal growth. In pregnancy, placental growth hormone stimulates maternal production of insulin-like growth factor I (IGF-I) (2-4) that could promote placental development and transfer of nutrients to the fetus (3, 5, 6) . Thus, some studies have reported that low maternal IGF-I is associated with low birth weight (3, 7) , but the association could not be confirmed by others (2, (8) (9) (10) .
The biologic activity of IGF-I is influenced by IGF binding proteins that leave only a fraction of IGF-I in its biologically active form. Maternal insulin-like growth factor binding protein 1 (IGFBP-1) increases early in pregnancy (9, 11, 12) , and high IGFBP-1 concentrations at the fetoplacental interface may inhibit cytotrophoblast invasion (13) and block the action of IGF-I (5, 14) . Thus, high concentrations of maternal IGFBP-1 have been associated with low birth size, as indicated by some (5, (8) (9) (10) (15) (16) (17) (18) (19) but not by other studies (11, 20, 21) .
On the other hand, low maternal IGFBP-1 concentrations may be related to relatively larger offspring (8) . It is known that women with strong maternal insulin resistance tend to deliver large babies (22) , and insulin resistance is also associated with low concentrations of IGFBP-1 (15, 23) . Strong insulin resistance in pregnancy may therefore provide a plausible link between low maternal IGFBP-1 and high birth weight (24) .
Few studies have assessed longitudinal patterns of maternal IGFs in pregnancy and fetal growth. In a randomly selected sample from a cohort of pregnant women, we therefore assessed whether maternal concentrations of IGF-I and IGFBP-1 measured in blood taken at different stages of pregnancy could be related to offspring birth weight.
MATERIALS AND METHODS
Between June 1992 and May 1994, 35,940 women in Norway participated in a prospective study of Toxoplasma gondii infection in pregnancy. All pregnant women who attended antenatal care in 11 of 19 counties were included in the study (25) . A blood sample was drawn from each woman in the first trimester and, in women without antibodies against T. gondii, additional blood samples were drawn in the second and third trimesters.
Subsequently to the original study, we attempted to contact all participating women by mail to obtain their consent to use the data and blood samples for additional scientific purposes, and 29,072 women consented. Previously, blood samples from this population have been used in studies of fetal death and preeclampsia (26) (27) (28) . From the cohort of pregnant women, we randomly selected 400 women without preeclampsia and excluded women with twin pregnancy (n ¼ 7), reported pregnancy length less than 23 or more than 44 weeks (n ¼ 11), offspring with serious malformations (n ¼ 11), or no available serum (n ¼ 3), leaving 368 women available for analysis.
We obtained information on pregnancy outcomes by linkage to the Medical Birth Registry of Norway (www.uib.no/ mfr). This registry has recorded information on all deliveries after 16 weeks of gestation since 1967. Information on each pregnancy is obtained by compulsory notification on standardized forms from the midwife or physician in charge of the delivery. We used information from the Medical Birth Registry in the analysis, including offspring sex, birth weight and length, and length of gestation at birth. Table 1 gives the number of women in whom IGF-I and IGFBP-1 could be measured in samples from the first trimester (median, 9 weeks of gestation; range, 4-12 weeks), second trimester (median, 22 weeks; range, 13-27 weeks), and third trimester (median, 38 weeks; range, 28-40 weeks). The number of measurements for each gestational week of serum sampling is shown in Web Table 1 , which appears on the Journal's Web site (http://aje.oxfordjournals.org).
Insulin-like growth factor I and insulin-like growth factor binding protein 1
The sera were treated according to uniform standards and stored in one place at À20°C until analysis. The sera had not been thawed between the initial time of storage and time of laboratory analyses. Concentrations of IGF-I and IGFBP-1 were determined by enzyme-linked immunosorbent assay (ELISA) (DSL-10-2800 nonextraction IGF-I ELISA; DSL-10-7800 total IGFBP-1 ELISA) (both from Diagnostics Systems Laboratories, Inc., Webster, Texas) according to the manufacturer's instructions. The IGF-I ELISA has a minimum detection limit of 2.06 ng/mL, and the IGFBP-1 ELISA has a minimum detection limit of 0.25 ng/mL. Approximately 1% of the samples had IGF-I concentrations below the detection limit, and these samples were assigned the half value of the minimal detection value. The technicians performing the hormone analyses were blinded to the clinical outcome.
Statistical analysis
We estimated z scores of birth weight, adjusted for gestational age and offspring sex, using the overall distribution of birth weight as registered in the Medical Birth Registry of Norway (29) . In the analyses, z scores were divided into the 3 categories of <20th percentile (n ¼ 78; mean birth weight, 2,934 g); >80th percentile (n ¼ 74; mean birth weight, 4,257 g), and 20th-80th percentile (n ¼ 216; mean birth weight, 3,577 g) of birth weight to reflect relatively small, relatively large, and normal-sized offspring.
For each birth weight category, we described the longitudinal pattern of maternal IGF-I and IGFBP-1 throughout the length of pregnancy. Thus, we calculated mean serum concentrations of IGF-I and IGFBP-1 for each week of gestation with adjustment for maternal age, using a multilevel mixed-effects linear regression model. In the model, the association of gestational week with IGF-I or IGFBP-1 was expressed by fractional polynomials.
For measurements within each trimester, we used multiple linear regression to examine if 1-standard deviation differences in IGF-I and IGFBP-1 were associated with birth weight (in grams). Among women who had serum samples from more than one trimester, we assessed whether changes in IGF-I and IGFBP-1 between trimesters could be associated with birth weight, and we related birth weight to 1-standard deviation change in each growth factor, on the basis of the distribution of change between trimesters. The results were adjusted for gestational week of serum sampling, gestational age at birth, offspring sex, and maternal age.
In similar analyses, we also used birth length (cm) and ponderal index (birth weight (kg)/birth length (m) 3 ) as the outcomes.
In a separate analysis of women with measurements in both the first and second trimesters, we assessed whether persistently low concentrations of IGF-I or persistently high concentrations of IGFBP-1 throughout pregnancy were associated with birth weight. Thus, we ranked women according to their concentrations of IGF-I and IGFBP-1 in the first and second trimester, using the median as cutoff for high versus low concentrations. In the analysis, we assessed whether combinations of ranks (high vs. low) in the first and second trimesters were related to offspring birth size, with adjustment for gestational weeks at blood sampling, gestational age at birth, offspring sex, and maternal age.
In a final analysis among women with IGFBP-1 measurements in all 3 trimesters, we explored whether offspring birth weight differed in women with IGFBP-1 below (n ¼ 26) or above (n ¼ 23) the median in all trimesters, compared with any other combination of rank (n ¼ 70).
In all analyses, we used square-root transformation to obtain normally distributed concentrations of IGF-I and IGFBP-1. All results were adjusted for maternal age; however, this adjustment did not substantially influence the estimates. Also, the results were essentially unchanged after additional adjustment for parity. STATA, version 10.1, software for Windows (StataCorp LP, College Station, Texas) was used for the statistical analyses.
The study was approved by the Norwegian Directorate for Health, the Norwegian Data Inspectorate, and the Regional Committee for Medical Research Ethics.
RESULTS
Descriptive characteristics of the study population are given in Table 1 .
IGF-I Figure 1 shows mean concentrations of IGF-I throughout pregnancy, according to the 3 categories of birth weight. The figure suggests that maternal IGF-I did not substantially differ according to the 3 categories. Thus, in women who delivered offspring with birth weight between the 20th and the 80th percentiles, IGF-I declined from around the 5th to the 12th weeks of gestation, from approximately 200 ng/mL to 130 ng/mL. During the second half of pregnancy, there was a gradual increase in IGF-I, with a maximum of approximately 300 ng/mL around term. For women who either delivered smaller (<20th percentile) or larger (>80th percentile) babies, IGF patterns were essentially similar to the pattern described above.
We assessed whether offspring birth weight was related to IGF-I, as measured in blood samples from each trimester. However, we found no statistically significant association with birth weight for either trimester and, also, there was no consistent pattern across the trimesters. Further, there were no associations of IGF-I with birth length or with ponderal index.
In women who had repeated measurements of IGF-I, we assessed changes in IGF-I associated with birth weight. We found that a 1-standard deviation stronger increase in IGF-I from the first to second trimester was associated with 82 g (95% confidence interval (CI): 11, 153) higher birth weight (Table 2 ). For birth length or ponderal index, there were no associations related to changes in IGF-I. We used the median value of IGF-I as cutoff and ranked women as being high or low in IGF-I in the first and the second trimesters. We assessed whether persistently low concentrations of IGF-I could be associated with birth weight (Table 3) but found no clear differences in birth weight associated with different combinations of rank for the 2 trimesters. Similarly, there were no differences in birth length and ponderal index associated with this ranking.
IGFBP-1 Figure 2 shows mean concentrations of IGFBP-1 in each pregnancy week according to offspring birth weight. In the beginning of pregnancy (around 5 weeks), IGFBP-1 did not differ according to the birth weight of the offspring, and the average concentration was about 20 ng/mL for all 3 categories of birth weight. Subsequently, there was a general increase in IGFBP-1, but the increase was particularly strong in women who later delivered relatively small offspring. Thus, at the end of the second trimester, the mean IGFBP-1 was approximately 100 ng/mL in women who delivered large offspring (>80th percentile), as compared with 120 ng/mL in women with middle-weight offspring (20th-80th percentiles), and 140 ng/mL in women who delivered small offspring (<20th percentile). In the third trimester, these concentrations were slightly lower than in the second trimester, but the differences persisted according to birth weight category.
We also analyzed maternal IGFBP-1 concentrations within each trimester and found that a 1-standard deviation higher IGFBP-1 in the second trimester was associated with a 71-g (95% CI: 14, 128) lower birth weight. Similarly, a 1-standard deviation higher IGFBP-1 in the third trimester was associated with an 83-g (95% CI: 23, 143) lower birth weight. IGFBP-1 in the first trimester was also negatively associated with birth weight, but this association was weaker and not statistically significant. Among women who had IGFBP-1 measurements in both the first and second trimester, there was a tendency that a strong increase in IGFBP-1 was associated with relatively lower birth weight; however, the association was not statistically significant (Table 2) .
We also ranked the women according to IGFBP-1 concentrations (at the median) in the first and second trimesters. An increase in IGFBP-1 from being below the median in the first to being above the median in the second trimester was associated with 342-g (95% CI: 124, 560) lower birth weight, compared with having low IGFBP-1 in both trimesters. Women with low IGFBP-1 concentrations in both trimesters delivered offspring who weighed between 200 and 350 g more than did women with other combinations of rank. These women also tended to deliver offspring with higher birth length and ponderal index, but these associations were not statistically significant (Table 3) .
Finally, we assessed birth weight in relation to IGFBP-1 across all 3 trimesters. We found that having IGFBP-1 below the median in all trimesters was associated with a 260-g (95% CI: 33, 487) higher birth weight, whereas having IGFBP-1 above the median in all trimesters was not associated with birth weight (41-g (95% CI: À211, 292) lower birth weight), compared with women with any other combination of rank.
DISCUSSION
In this population study of pregnant women without preeclampsia, having low IGFBP-1 throughout pregnancy was associated with relatively higher offspring birth weight. For IGF-I, there was no consistent relation with birth weight, but an increase from the first to second trimester was associated with relatively higher birth weight.
It is not clear how maternal IGF-I could influence fetal growth, because IGF-I does not cross over to the fetal circulation (10, 16) . Nonetheless, low maternal concentrations of IGF-I late in pregnancy have been associated with placental dysfunction and fetal growth restriction (3, 30) , and it has been suggested that low IGF-I may compromise placental development or disturb placental transfer of nutrients to the fetus (3, 5, 6) . Studies of apparently normal pregnancies (2, 3, 7-11, 16) have shown inconsistent results, and several studies have not reported any association of maternal IGF-I with birth weight (2, 3, 8-10 ). However, there is some evidence to suggest that a strong increase in maternal IGF-I in the middle of pregnancy (11), or high maternal IGF-I late in pregnancy (7, 16) , may be associated with higher offspring birth weight. High maternal IGF-I in the second and third trimesters may also be associated with relatively higher placental weight (2, 11, 16) , suggesting that IGF-I could stimulate placental growth and, thus, promote placental transfer of nutrients (2) . In pregnancy, IGFBP-1 is expressed in decidual tissue (20, 31) . It has been suggested that high levels of maternal IGFBP-1 could impair cytotrophoblast invasion (13) or inhibit IGF-I at the fetoplacental interface (14) and, in turn, lead to reduced fetal growth. Conversely, low IGFBP-1 could be related to greater fetal growth. In our data, women with low IGFBP-1 in both the first and second trimesters tended to deliver larger babies, and it seems plausible that this could be explained by underlying maternal glucose homeostasis. In the nonpregnant state, the liver is the main source of IGFBP-1 (23) , and hepatic IGFBP-1 is likely to contribute to maternal IGFBP-1 concentrations also in pregnancy (18, 20) . Insulin resistance is a physiologic adaptation in pregnancy and is characterized by high insulin concentrations (21) that may inhibit hepatic IGFBP-1 production (23). This situation may also result in excess fetal growth, which could be mediated by fetal hyperglycemia and hyperinsulinemia (22) . Thus, strong maternal insulin resistance may be a common cause of both low maternal concentrations of IGFBP-1 and higher offspring birth weight.
It has been suggested that a low level of maternal IGFBP-1 is associated with higher risk of gestational diabetes (15, 21) and term preeclampsia (28) , and both of these conditions appear to occur more often in women with strong insulin resistance. Moreover, maternal body weight and body fat have been inversely associated with maternal concentrations of IGFBP-1 (24) . These observations may strengthen the hypothesis that a low level of IGFBP-1 in pregnancy may be a result of maternal insulin resistance.
Insulin may also inhibit IGFBP-1 production in the fetus (1, 19, 32) and lead to higher concentrations of free, biologically active IGFs. Possibly, this situation could also contribute to excess fetal growth associated with strong maternal insulin resistance.
We studied a random sample from a large populationbased cohort of pregnant women, and the participants are likely to represent the general population of pregnant women without preeclampsia. The repeated blood sampling enabled us to assess birth weight related to changes in IGF-I and IGFBP-1 during pregnancy. We used several analytical approaches to assess the associations with birth weight, but the inverse association of IGFBP-1 with birth weight remained consistent across the analyses and is therefore not likely to be a chance finding. However, the blood samples were not collected in the fasting state and, in some women, IGFBP-1 could be low as the result of recent food intake, because insulin may closely regulate maternal hepatic IGFBP-1 production (23) . Whether this could influence the association of IGFBP-1 with birth weight is not clear. Maternal serum was stored at -20 o C for approximately 10 years before analyses. Storage time could also affect serum concentrations, but a possible deterioration in serum concentrations is not likely to differ systematically according to infant birth weight. In our sample, few women had offspring at the extremes of the birth weight distribution and, therefore, we could not specifically study the risk of severe excess growth or severely restricted fetal growth in relation to IGF-I or IGFBP-1.
In summary, this longitudinal study of pregnant women without preeclampsia showed that maternal IGFBP-1 is inversely associated with offspring birth weight, and that persistently low IGFBP-1 in pregnancy is associated with relatively higher birth weight. It seems plausible that maternal insulin resistance could provide a link between IGFBP-1 and the offspring's birth weight.
